|Description||Therapeutics based on Enzyme Modulation|
|Venture Round, 4/2013 |
|Series A, 11/2013 ||$11.5M|
|Debt, 5/2012 |
ALDEA Pharmaceuticals is developing small-molecule modulators of the aldehyde dehydrogenase enzyme (ALDH) family, to treat toxic aldehyde-related diseases. This proprietary technology represents new product opportunities to address novel targets across multiple therapeutic areas. For example, an ALDH activator compound enhances the detoxification of acetaldehyde in the alcohol metabolism pathway, to treat acute symptoms and to reduce long-term tissue damage and cancer risk.